⏳ Fetching live dividend data...
Home › Calculator › EPRSQ Dividend Calculator 2026
EPIRUS Biopharmaceuticals, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in EPRSQ → $1.02400512001152e+61M in 10 years · $853,337,173,341,013,400,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/month
EPIRUS Biopharmaceuticals, Inc. was a global pharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of biosimilar therapeutics. Its primary experimental compound was BOW015, a biosimilar counterpart to Remicade (infliximab), intended for the treatment of various inflammatory conditions. The company's developmental portfolio also encompassed several other biosimilar candidates: BOW050, a biosimilar version of Humira (adalimumab), targeting inflammatory diseases such as rheumatoid arthritis, various adult and pediatric forms of arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis. BOW070, mimicking Actemra (tocilizumab), aimed at rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. BOW080, a biosimilar to Soliris, designed to address ultra-rare blood disorders like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. BOW100, a biosimilar of SIMPONI, for inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. EPIRUS had established strategic alliances, including a licensing arrangement with Sun Pharmaceutical Industries Ltd., a joint licensing and collaboration pact with Livzon Mabpharm Inc., and a collaborative venture with Polpharma S.A. Founded in 2011, the firm maintained its corporate base in Boston, Massachusetts. However, on July 25, 2016, Epirus Biopharmaceuticals, Inc. initiated Chapter 7 liquidation proceedings by submitting a voluntary petition with the US Bankruptcy Court for the District of Massachusetts.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open EPRSQ position with:
Real after-tax yield depends on where you live and how you hold EPRSQ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 200000000.00% | 199999997.20% | $20,000,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 170000000.00% | 169999997.20% | $17,000,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 160000000.00% | 159999997.20% | $16,000,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 200000000.00% | 199999997.20% | $20,000,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 182500000.00% | 182499997.20% | $18,250,000,000 / yr |
| 🇨🇦 TFSA | 0% | 200000000.00% | 199999997.20% | $20,000,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 150000000.00% | 149999997.20% | $15,000,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 170000000.00% | 169999997.20% | $17,000,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 140000000.00% | 139999997.20% | $14,000,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 147250000.00% | 147249997.20% | $14,725,000,000 / yr |
| 🇫🇷 FR Taxable | 30% | 140000000.00% | 139999997.20% | $14,000,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
EPRSQ pays quarterly — 4 times per year. Next ex-div: TBD.
How EPRSQ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for EPRSQ sourced from FMP /financial-growth endpoint — real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the EPRSQ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) is currently trading at $0.00, trading near its 52-week low. The current dividend yield is 200000000.00% based on an annual payout of $2.00 per share.
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) is a healthcare stock currently trading at $0.00 with a dividend yield of 200000000.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever